Related Experiment Video
Updated: Jul 4, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Aspirin nonresponse in patients with arterial causes of ischemic stroke: considerations in detection and management
1Department of Neurology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. jbiller@lumc.edu
Patients with a history of ischemic stroke or transient ischemic attack (TIA) are at risk for recurrent ischemic events in the same or different vascular bed. Due to the central role of platelets in the spectrum of ischemic events in all vascular beds, antiplatelet therapy is a critical component of treatment. Of all antiplatelet therapies approved for the secondary prevention of stroke, aspirin is the most well-established and is recommended for all patients with a history of cerebrovascular disease. However, some patients do not respond to aspirin therapy and are termed "aspirin-resistant." This review discusses issues of, and possible solutions to, decreased platelet response to aspirin in patients with arterial causes of ischemic stroke.
Patients with a history of ischemic stroke or transient ischemic attack (TIA) are at risk for recurrent ischemic events in the same or different vascular bed. Due to the central role of platelets in the spectrum of ischemic events in all vascular beds, antiplatelet therapy is a critical component of treatment. Of all antiplatelet therapies approved for the secondary prevention of stroke, aspirin is the most well-established and is recommended for all patients with a history of cerebrovascular disease. However, some patients do not respond to aspirin therapy and are termed "aspirin-resistant." This review discusses issues of, and possible solutions to, decreased platelet response to aspirin in patients with arterial causes of ischemic stroke.
Related Concept Videos
Atherosclerosis IV: Nursing Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

